

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 451/02, 271/06, A61K 31/46, 31/42	A1	(11) International Publication Number: WO 96/31508 (43) International Publication Date: 10 October 1996 (10.10.96)
(21) International Application Number: PCT/EP96/01465 (22) International Filing Date: 2 April 1996 (02.04.96) (30) Priority Data: 9507203.9 7 April 1995 (07.04.95) GB (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): GASTER, Laramie, Mary [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). MULHOLLAND, Keith, Raymond [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). (74) Agent: SUMMERSELL, Richard, John; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).		(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: BIPHENYLAMIDE DERIVATIVES AS 5HT _{1D} ANTAGONISTS (57) Abstract Novel biphenyl amide derivatives as 5HT _{1D} antagonists, processes for their preparation, pharmaceutical compositions containing them and their use for the treatment of CNS disorders.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

BIPHENYLAMIDE DERIVATIVES AS 5HT_{1D} ANTAGONISTS

5 The present invention relates to novel amide derivatives, processes for their preparation, and pharmaceutical compositions containing them.

EPA 0 533 266/7/8 disclose a series of benzanilide derivatives which are said to possess 5HT_{1D} receptor antagonist activity. These compounds are said to be of use in the treatment of various CNS disorders.

10 A structurally distinct class of compounds have now been discovered and have been found to exhibit 5HT_{1D} receptor antagonist activity. In a first aspect, the present invention therefore provides a compound of formula (I) or a salt or N-oxide thereof:



(I)

20 in which

R¹ is hydrogen, halogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, COC₁₋₆alkyl, C₁₋₆alkoxy, hydroxy, hydroxyC₁₋₆alkyl, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkoxy, acyl, nitro, trifluoromethyl, cyano, SR⁹, SOR⁹, SO₂R⁹, SO₂NR¹⁰R¹¹, CO₂R¹⁰, NR¹⁰SO₂R¹¹, CONR¹⁰R¹¹, CO₂NR¹⁰R¹¹, CONR¹⁰(CH₂)_aCO₂R¹¹, (CH₂)_aNR¹⁰R¹¹, (CH₂)_aCONR¹⁰R¹¹, (CH₂)_aNR¹⁰COR¹¹, (CH₂)_aCO₂C₁₋₆alkyl, CO₂(CH₂)_aOR¹⁰, CONHNR¹⁰R¹¹, NR¹⁰R¹¹, NR¹⁰CO₂R¹¹, NR¹⁰CO(CH₂)_aNR¹⁰R¹¹, NR¹⁰CONR¹⁰R¹¹, CR¹⁰=NOR¹¹, CNR¹⁰=NOR¹¹, where R⁹, R¹⁰ and R¹¹ are independently hydrogen or C₁₋₆alkyl and a is 1 to 4 or R¹ is an optionally substituted 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur;

R² and R³ are independently hydrogen, halogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkenyl, C₁₋₆alkoxy, hydroxyC₁₋₆alkyl, C₁₋₆alkylOC₁₋₆alkyl, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO₂R¹⁰, CONR¹⁰R¹¹, NR¹⁰R¹¹ where R¹⁰ and R¹¹ are independently hydrogen or C₁₋₆alkyl;

35 R⁴ is hydrogen or C₁₋₆alkyl and R⁵ is hydrogen, halogen, hydroxy, C₁₋₆alkyl or

- C₁₋₆alkoxy or R⁴ and R⁵ together form a group -A- where A is (CR¹²R¹³)_q where q is 2, 3 or 4 and R¹² and R¹³ are independently hydrogen or C₁₋₆alkyl or A is (CR¹²R¹³)_r-D where r is 0, 1, 2 or 3 and D is oxygen, sulphur or CR¹²=CR¹³;
 R⁶ is hydrogen, halogen, hydroxy, C₁₋₆alkyl or C₁₋₆alkoxy;
- 5 n is 1 or 2; and
 R⁷ is an optionally substituted 5 to 7-membered saturated or partially saturated heterocyclic ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen or sulphur or R⁷ is an optionally substituted 6,6 or 6,5 bicyclic ring containing a nitrogen atom and optionally a further heteroatom selected from oxygen, nitrogen or sulphur.
- 10 C₁₋₆alkyl groups, whether alone or as part of another group, may be straight chain or branched.
- Suitably R¹ is hydrogen, halogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, COC₁₋₆alkyl, C₁₋₆alkoxy, hydroxy, hydroxC₁₋₆alkyl, hydroxC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkoxy, acyl, nitro, trifluoromethyl, cyano, SR⁹, SOR⁹, SO₂R⁹, SO₂NR¹⁰R¹¹, CO₂R¹⁰,
 15 NR¹⁰SO₂R¹¹, CONR¹⁰R¹¹, CO₂NR¹⁰R¹¹, CONR¹⁰(CH₂)_aCO₂R¹¹, (CH₂)_aNR¹⁰R¹¹, (CH₂)_aCONR¹⁰R¹¹, (CH₂)_aNR¹⁰COR¹¹, (CH₂)_aCO₂C₁₋₆alkyl, CO₂(CH₂)_aOR¹⁰, CONHNR¹⁰R¹¹, NR¹⁰R¹¹, NR¹⁰CO₂R¹¹, NR¹⁰CO(CH₂)_aNR¹⁰R¹¹, NR¹⁰CONR¹⁰R¹¹, CR¹⁰=NOR¹¹, CNR¹⁰=NOR¹¹, where R⁹, R¹⁰ and R¹¹ are independently hydrogen or C₁₋₆alkyl and a is 1 to 4.
- 20 When R¹ is an optionally substituted 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur, suitable heterocyclic rings include thienyl, furyl, pyrrolyl, triazolyl, diazolyl, imidazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl and pyrazinyl. The heterocyclic rings can be linked to the remainder of the molecule via a carbon atom or, when present, a nitrogen
 25 atom. Preferably R¹ is oxadiazolyl, most preferably a 5-methyl-1,2,4-oxadiazol-3-yl group.
- Suitably R² and R³ are independently hydrogen, halogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkenyl, C₁₋₆alkoxy, hydroxC₁₋₆alkyl, C₁₋₆alkylOC₁₋₆alkyl, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO₂R¹⁰, CONR¹⁰R¹¹,
 30 NR¹⁰R¹¹ where R¹⁰ and R¹¹ are hydrogen or C₁₋₆alkyl. Preferably R² is C₁₋₆alkyl, in particular methyl. Preferably R³ is hydrogen.
- Suitably R⁴ is hydrogen or C₁₋₆alkyl and R⁵ is hydrogen, halogen, hydroxy, C₁₋₆alkyl or C₁₋₆alkoxy or R⁴ and R⁵ together form a group -A- where A is (CR¹²R¹³)_q where q is 2, 3 or 4 and R¹² and R¹³ are independently hydrogen or C₁₋₆alkyl or A is
 35 (CR¹²R¹³)_r-D where r is 0, 1, 2 or 3 and D is oxygen, sulphur or CR¹²=CR¹³. Preferably R⁴ and R⁵ are both hydrogen or R⁴ and R⁵ are linked to form a group A.

Preferably A is $(CR^{12}R^{13})_q$ where R^{12} and R^{13} are both hydrogen and q is 2 or 3 such that A forms an ethyl or propyl linkage.

Suitably R^6 is hydrogen, halogen, hydroxy, C_{1-6} alkyl or C_{1-6} alkoxy. Preferably R^6 is C_{1-6} alkoxy, in particular methoxy. Suitably n is 1 or 2, preferably n is 1.

- 5 Suitably R^7 is an optionally substituted 5 to 7-membered saturated or partially saturated heterocyclic ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen or sulphur. Examples of such groups include piperidine and tetrahydropyridine. Alternatively R^7 is a 6,6 or 6,5 bicyclic ring containing a nitrogen atom and optionally a further heteroatom selected from oxygen, nitrogen or sulphur. Examples of such
- 10 groups include tropane, isoquinuclidine and granatane rings. Optional substituents for such ring systems include C_{1-6} alkyl, such as methyl. For example, R^7 groups containing a nitrogen atom can be substituted on the nitrogen atom by a methyl group.

The groups R^1 , R^2 and R^3 can be attached to their respective rings at any suitable position.


- 15 Particularly preferred compounds of the invention include:
- N-[4-Methoxy-3-(1-methyl-4-piperidinyl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
- N-[4-Methoxy-3-(4-piperidinyl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
- 20 N-[4-Methoxy-3-(1-methyl-1,2,3,6-tetrahydropyrid-4-yl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
- N-[3-(8-Azabicyclo[3.2.1]octan-3-yl)-4-methoxyphenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
- N-[4-Methoxy-3-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenyl]-2'-methyl-4'-(5-methyl-
- 25 1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
- [3,4-Dihydro-6-methoxy-7-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-2H-quinolin-1-yl]-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone,
- [7-(8-Azabicyclo[3.2.1]octan-3-yl)-3,4-dihydro-6-methoxy-2H-quinolin-1-yl]-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone,
- 30 N-[3-(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
- and pharmaceutically acceptable salts thereof.

- Preferred salts of the compounds of formula (I) are pharmaceutically acceptable salts. These include acid addition salts such as hydrochlorides, hydrobromides,
- 35 phosphates, acetates, fumarates, maleates, tartrates, citrates, oxalates, methanesulphonates and p-toluenesulphonates.


Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and the mixtures thereof including racemates. Tautomers of compounds of formula (I) and mixtures thereof also form an aspect of the invention.

5 In a further aspect the present invention provides a process for the preparation of a compound of formula (I) which comprises.

(a) for compounds where R^4 is hydrogen or C_{1-6} alkyl and R^5 is hydrogen, halogen, hydroxy, C_{1-6} alkyl or C_{1-6} alkoxy, reaction of a compound of formula (II):




in which R^1 , R^2 and R^3 are as defined in formula (I) and L is a leaving group, with a compound of formula (III):



20 in which R^4 and R^5 are as defined above and R^6 , R^7 and n are as defined in formula (I);
or

(b) where R^4 together with R^5 forms a group A, reaction of a compound of formula (II) as defined above with a compound of formula (IV):




30 in which A is as defined above and R^6 , R^7 and n are as defined in formula (I);
and optionally after (a) or (b) and in any order:

- converting a compound of formula (I) into another compound of formula (I)
- forming a pharmaceutically acceptable salt.

Suitable activated carboxylic acid derivatives of formula (II) include acyl halides and acid anhydrides. Activated compounds of formula (II) can also be prepared by reaction of the corresponding carboxylic acid with a coupling reagent such as carbonyldiimidazole, dicyclohexylcarbodiimide or diphenylphosphorylazide. Preferably the group L is halo, particularly chloro.

Alternatively L is an ester forming group such that the resulting esters of formula (II) can be reacted with compounds of formula (III) in the presence of an organo-aluminium reagent such as trimethylaluminium. Such a reaction is typically carried out in the presence of an inert solvent such as toluene.

A compound of formula (II) is typically reacted with a compound of formula (III) or (IV) in an inert organic solvent such as DMF, THF or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine. Compounds of formula (II) can be prepared from a compound of formula (V):



(V)

in which R¹, R² and R³ are as defined in formula (I) using standard procedures. For example acid chlorides can be prepared by reaction with phosphorous pentachloride, oxalyl chloride or thionyl chloride. Acid anhydrides can be prepared by reaction with a suitable acid anhydride, for example trifluoroacetic anhydride.

Intermediate compounds of formula (V) are commercially available or can be prepared using standard procedures such as those outlined in EPA 533266/7/8 and GB A 2 276 160. Intermediate compounds of formulae (III) and (IV) can be prepared using standard procedures known in the art. Certain intermediate compounds of formulae (III) and (IV) are novel and form a further aspect of the invention.

It will be appreciated to those skilled in the art that it may be necessary to protect certain reactive substituents during some of the above procedures. Standard protection and deprotection techniques can be used. For example, primary amines can be protected as phthalimide, benzyl, benzyloxycarbonyl or trityl derivatives. These groups can be removed by conventional procedures well known in the art.

Carboxylic acid groups can be protected as esters. Aldehyde or ketone groups can be protected as acetals, ketals, thioacetals or thioketals. Deprotection is achieved using standard conditions.

Certain compounds of formula (I) can be converted into further compounds of formula (I) using standard procedures.

5 5HT_{1D} Antagonists, and in particular the compounds of the present invention, are expected to be of use in the treatment of CNS disorders such as mood disorders, including depression, seasonal effective disorder and dysthymia; anxiety disorders, including
10 generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder, memory disorders, including dementia, amnesic disorders and age-associated memory impairment; and disorders of eating behaviours, including anorexia nervosa and bulimia nervosa. Other CNS disorders include
10 motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders.

15 5HT_{1D} Antagonists, and in particular compounds of the present invention, may also be of use in the treatment of endocrine disorders such as hyperprolactinaemia, in the treatment of vasospasm (particularly in the cerebral vasculature) and hypertension, as well
15 as disorders in the gastrointestinal tract where changes in motility and secretion are involved. They may also be of use in the treatment of sexual dysfunction.

Therefore, the present invention, provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in therapy.

20 The present invention also provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment of the
20 aforementioned disorders.

In another aspect the invention provides the use of a compound of general formula (I) or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a
25 medicament for the treatment of the aforementioned disorders.

25 In a further aspect the invention provides a method of treating the aforementioned disorders which comprises administering an effective amount to a patient in need of such
25 treatment of a compound of general formula (I) or a pharmaceutically acceptable salt or solvate thereof.

30 In particular the invention provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment or prophylaxis of
30 depression.

It will be appreciated by those skilled in the art that the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, different antidepressant agents.

35 The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.

Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tableting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.

For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.

The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.

The following example illustrate the invention.

Description 1**1-Carbomethoxy-4-(2-methoxyphenyl)piperidine**

1-Methyl-4-(2-methoxyphenyl)piperidine (J. Org. Chem. 1947, 12, 885-93) (3.02g, 14.73
5 mmol) was dissolved in dichloromethane (100 ml) and was treated with 1-chloroethyl
chloroformate (1.07 ml, 19.15 mmol), followed by diisopropylethylamine (2.57 ml, 14.73
mmol) with stirring under argon. After 16 h, the reaction mixture was evaporated under
reduced pressure and dissolved in methanol (100 ml). The reaction mixture was then
heated to reflux. After 0.5 h, the reaction mixture was allowed to cool, was evaporated
10 under reduced pressure and was dried *in vacuo* to give a buff solid, which was redissolved
in dichloromethane (100 ml) and treated with methyl chloroformate (1.14 ml, 14.73
mmol), followed by triethylamine (2.05 ml, 14.73 mmol) with stirring. After 24h the
reaction mixture was washed with NaHCO₃ solution (1X), water (1X) and 10% citric acid
(2X). The organic layer was then dried (Na₂SO₄) and evaporated under reduced pressure
15 to give an orange oil that crystallised on standing. The solid was recrystallised from 60-80
petrol to give the title compound as cream coloured crystals (1.05g, 30%).

m.pt 78-79°C

20 ¹H NMR (250 MHz, CDCl₃) δ (ppm): 7.20 (m, 2H), 6.90 (m, 2H), 4.30 (brs, 2H), 3.88
(s, 3H), 3.70 (s, 3H), 3.11 (m, 1H), 2.91 (t, 2H), 1.80 (m, 2H), 1.60 (m, 2H).

Description 2**4-(5-Amino-2-methoxyphenyl)-1-carbomethoxypiperidine**

25 The product from description 1 (0.500g, 2.01 mmol) was dissolved in Ac₂O (30 ml) and
was cooled to 0° C. Freshly ground copper (II) nitrate hemipentahydrate (0.561g, 2.41
mmol) was then added slowly (over 5 minutes). The reaction mixture was then allowed to
warm to room temperature and was stirred at room temperature for 1h. The reaction
30 mixture was then treated with water (30 ml), stirred for a further 0.5 h and then sodium
bicarbonate (solid) was added until pH8 was reached. The resultant blue solution was then
extracted with dichloromethane (2X). The combined organic layers were then dried
(Na₂SO₄) and evaporated under reduced pressure to give a yellow oil which was dried *in*
vacuo (0.501g). The oil was then redissolved in ethanol (40 ml) and was hydrogenated at
35 atmospheric pressure in the presence of 10% PdC (0.05g). After 5h, the reaction mixture
was filtered through kieselguhr. The filter pad was washed with EtOH and the filtrate was
evaporated under reduced pressure to give a brown oil which was dried *in vacuo*. The oil

was purified by SiO₂ chromatography (Et₂O as eluant) to give the title compound as an off white solid (0.150g, 33%).

¹H NMR (200 MHz, CDCl₃) δ (ppm): 6.70 (d, 1H), 6.20 (m, 2H), 4.70 (brs, 2H), 3.75 (s, 3H), 3.70 (s, 3H), 3.40 (s, 2H), 3.05 (m, 1H), 2.85 (t, 2H), 1.78 (m, 2H), 1.60 (m, 2H).

Description 3

4-(5-Amino-2-methoxyphenyl)-1-methylpiperidine

The product from description 2 (0.143g, 0.542 mmol) was dissolved in dry THF (10 ml), and was treated with lithium aluminium hydride (0.041g, 1.084 mmol) and was heated to reflux with stirring under argon. After 2h, the reaction mixture was allowed to cool and water (0.041 ml) was added, followed by 10% NaOH (0.063 ml) and water (0.104 ml). The mixture was then stirred at room temperature for 0.5 h, before being filtered through kieselguhr. The filter pad was then washed with dry THF (2X), and the filtrate was evaporated under reduced pressure and dried *in vacuo* to give the title compound as a brown oil (0.103g, 86%).

¹H NMR (250 MHz, CDCl₃) δ (ppm): 6.68 (d, 1H), 6.58 (d, 1H), 6.50 (dd, 1H), 3.75 (s, 3H), 3.39 (s, 2H), 2.90 (m, 3H), 2.31 (s, 3H), 2.05 (dt, 2H), 1.75 (m, 4H).

Description 4

N-[3-(1-Carbomethoxy-4-piperidiny)-4-methoxyphenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide

25

The product from description 2 (0.130g, 0.492 mmol) was transformed to give the title compound (0.213g, 85%) as a white foam, according to the method described in example 1.

¹H NMR (250 MHz, CDCl₃) δ(ppm): 7.97 (m, 4H), 7.81 (s, 1H), 7.55 (dd, 1H), 7.48 (d, 2H), 7.38 (m, 2H), 6.90 (d, 1H), 4.30 (brs, 2H), 3.85 (s, 3H), 3.70 (s, 3H), 3.12 (m, 1H), 2.88 (t, 2H), 2.70 (s, 3H), 2.30 (s, 3H), 1.82 (m, 2H), 1.62 (m, 2H).

Description 5

N-[3-Bromo-4-methoxyphenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide

- 5 4-Methoxy-3-bromoaniline (0.521g, 0.258 mmol) was transformed to give the **title compound** (0.920g, 75%) as a cream solid according to the method outlined in example 1.

¹H NMR (250 MHz, CDCl₃) δ (ppm): 7.90 (m, 6H), 7.61 (dd, 1H), 7.48 (d, 2H), 7.35 (d, 1H), 6.90 (d, 1H), 3.90 (s, 3H), 2.70 (s, 3H), 2.30 (s, 3H).

10

Description 6

N-[3-(4-Pyridyl)-4-methoxyphenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide

- 15 The product from description 5 (0.400g, 0.837 mmol) was transformed to give the **title compound** (0.162g, 41%) as an off white solid according to the method outlined in EP 0533 267A1, Intermediate 23.

20 ¹H NMR (200 MHz, CDCl₃) δ (ppm): 8.62 (d, 2H), 8.10 (s, 1H), 7.97 (m, 4H), 7.67 (m, 2H), 7.50 (m, 4H), 7.31 (d, 1H), 7.03 (d, 1H), 3.85 (s, 3H), 2.70 (s, 3H), 2.30 (s, 3H).

Description 7

3-Hydroxy-3-(2-methoxyphenyl)-8-methyl-8-azabicyclo[3.2.1]octane

- 25 A stirred solution of 2-bromoanisole (9.25 ml, 0.074 mol) in dry diethyl ether (110 ml) under argon was cooled to 0° C and was treated with n-butyllithium (1.6M) (45.6 ml, 0.073 mol) slowly. The reaction mixture was then allowed to warm to room temp. After 0.5 h, a solution of tropinone (10.14g, 0.073 mol) in dry diethyl ether (60 ml) was added causing the reaction mixture to reflux. Reflux was maintained for a further 0.5 h, before
- 30 the reaction mixture was allowed to cool. Water (40 ml) was then added and the reaction mixture was stirred for 0.25 h. The organic layer was then separated, dried (Na₂SO₄) and evaporated under reduced pressure to give a pale yellow oily solid, which was triturated with petroleum ether (60-80). The resultant suspension was then filtered to give the **title compound** as a white solid, which was dried *in vacuo* (9.04g, 50%).

35

¹H NMR (250 MHz, CDCl₃) δ (ppm): 7.32 (dd, 1H), 7.20 (m, 1H), 6.90 (m, 2H), 4.01 (s, 1H), 3.89 (s, 3H), 3.22 (m, 2H), 2.41 (m, 1H), 2.35 (s, 3H), 2.30 (m, 3H), 2.02 (m, 4H).

5 Description 8

3-(2-Methoxyphenyl)-8-methyl-8-azabicyclo[3.2.1]octane

The product from Description 7 (8.00g, 0.032 mol) was added slowly to trifluoroacetic acid (80 ml) with stirring and heated to reflux. After 1 h, the reaction mixture was
10 evaporated under reduced pressure and partitioned between 10% NaOH and CH₂Cl₂. The aqueous layer was then extracted with CH₂Cl₂ (2x) and the combined organic layers were dried (Na₂SO₄) and evaporated under reduced pressure to give a yellow oil which was dried *in vacuo*. The oil was redissolved in ethanol (100 ml) and was hydrogenated at atmospheric pressure in the presence of 10% PdC (1g) at 40° C. After 5 h, the reaction
15 mixture was filtered through kieselguhr and the filter pad was washed with ethanol. The filtrate was then evaporated under reduced pressure to give the title compound as a yellow oil that crystallised on standing (6.68g, 90%).

¹H NMR (200 MHz, CDCl₃) δ (ppm): 7.21 (dd, 1H), 7.12 (dd, 1H), 6.92 (d, 1H), 6.80 (d, 1H), 3.80 (s, 3H), 3.40 (t, 1H), 3.30 (m, 2H), 2.48 (m, 2H), 2.30 (s, 3H), 2.10 (m, 2H),
20 1.48 (m, 4H).

Description 9

3-(2-Methoxyphenyl)-8-tert-butoxycarbonyl-8-azabicyclo[3.2.1] octane

25

3-(2-Methoxyphenyl)-8-methyl-8-azabicyclo[3.2.1]octane (D8, 6.66g, 0.029 mol) was dissolved in dichloromethane (200 ml) and was treated with 1-chloroethyl chloroformate (4.07 ml, 0.037 mol), followed by diisopropylethylamine (5.05 ml, 0.029 mol) with stirring at room temperature. After 20 h, the reaction mixture was evaporated under
30 reduced pressure and the orange/brown oily residue was dried *in vacuo*. The oil was then redissolved in methanol (150 ml) and heated to reflux. After 0.5 h, the reaction mixture was allowed to cool and was evaporated under reduced pressure to give a brown oil. The oil was dried *in vacuo* and then redissolved in dichloromethane (100 ml). The resultant solution was then stirred at room temp. and triethylamine (4.50 ml, 0.032 mol) was added,
35 followed by a solution of di-tert-butyl dicarbonate (6.96g, 0.032 mol) in dichloromethane (50 ml). After 2 h, the reaction mixture was washed with water (2X), dried (Na₂SO₄) and evaporated under reduced pressure to give a brown oil, which was purified by silica-gel

chromatography (1:1, petrol:diethyl ether) to give the title compound (8.84g, 100%) as a colourless oil that crystallised on standing.

¹H NMR (200 MHz, CDCl₃) δ (ppm): 7.12 (d, 2H), 6.90 (d, 1H), 6.82 (d, 1H), 4.28 (m, 2H), 3.80 (s, 3H), 3.02 (m, 1H), 2.45 (m, 2H), 2.05 (m, 2H), 1.65 (m, 2H), 1.52 (s, 9H), 1.48 (m, 2H).

Description 10

3-(5-Amino-2-methoxyphenyl)-8-tert-butoxycarbonyl-8-azabicyclo[3.2.1]octane

10

3-(2-Methoxyphenyl)-8-tert-butoxycarbonyl-8-azabicyclo[3.2.1]octane (D9, 4.40g, 0.014 mol) was dissolved in acetic anhydride (15 ml) and cooled to 0°C. Freshly ground copper (II) nitrate trihydrate (4.07g, 0.017 mol) was then added with stirring over 15 minutes.

The reaction mixture was then allowed to warm to room temperature. After 1h, the reaction mixture was added slowly to an excess of sodium carbonate solution to give a pale blue suspension, which was extracted with dichloromethane (2x70 ml). The combined organic layers were then dried (Na₂SO₄) and evaporated under reduced pressure to give a brown oil which was partly purified by silica gel chromatography (2:1-1:1 petrol (60-80): Et₂O as eluant) to give a pale yellow oil (1.34g) which was redissolved in ethanol (50 ml) treated with 10% PdC (0.3g) and hydrogenated at atmospheric pressure at 35°C. After 5h, the reaction mixture was filtered through kieselguhr and the filter pad washed with ethanol. The filtrate was then evaporated under reduced pressure and the resultant brown oil was purified by silica-gel chromatography (3:1, petrol (60-80): Et₂O) to give the title compound as a brown oil (0.550g, 12%).

25

¹H NMR (200 MHz, CDCl₃) δ (ppm): 6.68 (d, 1H), 6.50 (m, 2H), 4.25 (m, 2H), 3.70 (s, 3H), 3.40 (s, 2H), 2.91 (m, 1H), 2.40 (m, 2H), 2.03 (m, 2H), 1.62 (m, 2H), 1.51 (s, 9H), 1.40 (m, 2H).

30 Description 11

3-(5-Amino-2-methoxyphenyl)-8-methyl-8-azabicyclo[3.2.1]octane

3-(5-Amino-2-methoxyphenyl)-8-tert-butoxycarbonyl-8-azabicyclo[3.2.1] octane (D10, 0.385g, 1.16 mmol) was dissolved in dry THF (30 ml) with stirring and was treated with lithium aluminium hydride (0.088g, 2.32 mmol) under argon. The reaction mixture was then heated to reflux. After 2 h and 4 h, further amounts of lithium aluminium hydride (0.132g, 3.48 mmol) were added. Reflux was then maintained for a further 4 h, before the

35

reaction mixture was allowed to cool. Water (0.352 ml) was then added, followed by 10% NaOH (0.528 ml) and water (0.880 ml). The mixture was then stirred for 0.5 h before being filtered through kieselguhr. The filter pad was then washed with THF (20 ml) and the filtrate evaporated under reduced pressure to give the title compound as a brown solid (0.242g, 85%).

¹H NMR (250 MHz, CDCl₃) δ (ppm): 6.65 (d, 1H), 6.58 (d, 1H), 6.48 (dd, 1H), 3.70 (s, 3H), 3.40 (s, 2H), 3.30 (m, 1H), 3.20 (m, 2H), 2.38 (m, 2H), 2.22 (s, 3H), 2.08 (m, 2H), 1.50 (m, 2H), 1.40 (m, 2H)

Description 12

N-[3-(8-tert-Butoxycarbonyl-8-azabicyclo[3.2.1]octan-3-yl)-4-methoxyphenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide

3-(5-Amino-2-methoxyphenyl)-8-tert-butoxycarbonyl-8-azabicyclo[3.2.1] octane (D10, 0.130g, 0.392 mmol) was transformed according to the method of Example 1 to give the title compound (0.202g, 85%) as a cream foam.

¹H NMR (250 MHz, CDCl₃) δ (ppm): 8.02 (s, 1H), 7.95 (m, 3H), 7.81 (s, 1H), 7.48 (m, 4H), 7.32 (d, 1H), 6.82 (d, 1H), 4.28 (m, 2H), 3.80 (s, 3H), 3.05 (m, 1H), 2.70 (s, 3H), 2.45 (m, 2H), 2.31 (s, 3H), 2.05 (m, 2H), 1.65 (m, 2H), 1.51 (s, 9H), 1.45 (m, 2H)

Description 13

6-Methoxy-7-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)quinoline

The product from description 11 (0.642g, 2.61 mmol) was treated with glycerol (0.360g, 3.91 mmol), and iodine (0.014g). Concentrated sulphuric acid (0.720g, 7.57 mmol) was then added dropwise with stirring. The reaction mixture was then heated to 190°C. After 2 h, the reaction mixture was allowed to cool and the resultant brown gum was dissolved in water and 10% sodium hydroxide solution was added until pH14 was reached. The resultant suspension was then extracted with chloroform (4x). The combined extracts were then dried (Na₂SO₄) and evaporated under reduced pressure to give a dark brown oil which was dried *in vacuo*. The oil was purified by silica-gel chromatography (100:20:1 CH₂Cl₂: MeOH:NH₃ as eluant) to give the title compound as a pale brown oil (0.453g, 62%).

¹H NMR (250 MHz, CDCl₃) δ (ppm): 8.71 (dd, 1H), 8.01 (d, 1H), 7.92 (s, 1H), 7.30 (dd, 1H), 7.0 (s, 1H), 3.90 (s, 3H), 3.55 (t, 1H), 3.30 (m, 2H), 2.53 (m, 2H), 2.30 (s, 3H), 2.12 (m, 2H), 1.58 (m, 4H).

5 **Description 14**

6-Methoxy-7-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1,2,3,4-tetrahydroquinoline

The product from description 13 (0.443g, 1.57 mmol) was dissolved in ethanol (50 ml) and was treated with PtO₂ (0.1g). The resultant mixture was then hydrogenated at 50 psi. After 19h, the reaction mixture was filtered through kieselguhr. The filter pad was washed with ethanol and the filtrate evaporated under reduced pressure and dried *in vacuo* to give the title compound as a cream foam (0.44g, 98%).

¹H NMR (200 MHz, CDCl₃) δ (ppm): 6.50 (d, 2H), 3.72 (s, 3H), 3.60 (m, 2H), 3.48 (m, 1H), 3.22 (t, 2H), 2.70 (m, 4H), 2.60 (s, 3H), 2.20-1.85 (m, 9H).

Description 15

8-Methyl-3-trifluoromethylsulphonyloxy-8-azabicyclo[3.2.1]oct-2-ene

A stirred solution of tropinone (1.70g, 0.012 mol) in dry THF (20 ml) was cooled to -78°C under argon and was treated with a solution of LDA (2.0M in heptane/THF/ethylbenzene) (6.50 ml, 0.013 mol). After 1h, a solution of N-phenyltrifluoromethanesulphonimide (4.29g, 0.012 mol) in dry THF (15 ml) was added at -70°C. After addition was complete, the cooling bath was removed and the reaction mixture was allowed to warm to room temp. After a further 16h, the resulting pale yellow solution was evaporated under reduced pressure and dried *in vacuo* to give an orange oil. The oil was then purified by chromatography on neutral alumina (8.1 Petrol:EtOAc as eluant) to give the title compound as a yellow oil (2.34g, 72%).

¹H NMR (250 MHz, CDCl₃) δ (ppm): 5.82 (d, 1H), 3.47 (m, 2H), 2.82 (dd, 1H), 2.40 (s, 3H), 2.20-1.90 (m, 4H), 1.65 (m, 1H).

Description 16

8-Methyl-3-(3-nitrophenyl)-8-azabicyclo[3.2.1]oct-2-ene

35

8-Methyl-3-trifluoromethylsulphonyloxy-8-azabicyclo[3.2.1] oct-2-ene (D15) (0.400g, 1.48 mmol) was dissolved in DME (10 ml) and lithium chloride (0.188g, 4.44 mmol) was

added followed by 3-nitrobenzeneboronic acid (0.284g, 1.70 mmol), and 2M sodium carbonate solution (4 ml). Argon was then bubbled through the mixture and after 5 minutes Pd(PPh₃)₄ (0.086g, 0.074 mmol) was added. The mixture was then heated to reflux with stirring. After 4.5h the reaction mixture was allowed to cool and was left at room temp. for 12h, before being partitioned between chloroform and water. The aqueous layer was then extracted with chloroform (2X) and the combined organic layers were dried (Na₂SO₄) and evaporated under reduced pressure to give a brown oil that was dried *in vacuo*. The oil was purified by silica-gel chromatography (200:10.1, CH₂Cl₂MeOH:NH₃ as eluant) to give the title compound as a brown oil (0.147g, 46%).

10

¹H NMR (200 MHz, CDCl₃) δ (ppm): 8.20 (t, 1H), 8.08 (dd, 1H), 7.70 (d, 1H), 7.50 (t, 1H), 6.42 (d, 1H), 3.52 (m, 2H), 2.95 (m, 2H), 2.49 (s, 3H), 2.30-2.00 (m, 2H), 1.95 (m, 1H), 1.62 (m, 1H).

15 **Description 17****8-Methyl-3-(3-aminophenyl)-8-azabicyclo[3.2.1]octane**

8-Methyl-3-(3-nitrophenyl)-8-azabicyclo[3.2.1]oct-2-ene (D16) (0.146g, 0.598 mmol) was dissolved in ethanol (25 ml) and was hydrogenated at atmospheric pressure in the presence of 10% PdC (0.1g) at 50°C. After 2h, the reaction mixture was allowed to cool to room temp. and hydrogenation was continued for a further 16h. The reaction mixture was then filtered through kieselguhr and the filter pad was washed with ethanol. The filtrate was then evaporated under reduced pressure to give the title compound as a pale yellow oil, which was dried *in vacuo* (0.104g, 81%).

25

¹H NMR (250 MHz, CDCl₃) δ (ppm): 7.07 (t, 1H), 6.70 (d, 1H), 6.60 (s, 1H), 6.50 (dd, 1H), 3.65 (s, 2H), 3.33 (m, 2H), 3.00 (m, 1H), 2.50 (m, 2H), 2.38 (s, 3H), 2.05 (m, 2H), 1.75 (dd, 2H), 1.55 (d, 2H)

30

Example 1**N-[4-Methoxy-3-(1-methyl-4-piperidinyl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide**

2'-Methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxylic acid (E.P. 0533268A1) (0.145g, 0.492 mmol) was suspended in CH₂Cl₂ (7ml) and was treated with oxalyl chloride (0.064 ml, 0.738 mmol), followed by a drop of dry DMF, with stirring. After 2h,

the reaction mixture was evaporated under reduced pressure to give the crude acid chloride as a pale yellow solid which was dried *in vacuo*. The crude acid chloride was then redissolved in dichloromethane (7 ml), triethylamine (0.068 ml, 0.492 mmol) was then added, followed by a solution of the product from description 3 (0.103g, 0.468 mmol) in dichloromethane (2 ml) and the mixture was stirred at room temperature for 4 h before being washed with sodium bicarbonate solution (1X). The organic layer was then dried (Na₂SO₄) and evaporated under reduced pressure to give a brown oil which was purified by silica-gel chromatography (7.5% MeOH/CH₂Cl₂ as eluant) and prep. t.l.c. (20% MeOH/EtOAc) to give the **title compound** as a pale yellow oil 10.072g, 30%, which was converted to its oxalate salt.

m.pt 180-182° C (oxalate salt)

¹H NMR (200 MHz, CD₃OD) δ (ppm) (oxalate salt): 8.06 (m, 3H), 7.97 (d, 1H), 7.62 (s, 1H), 7.52 (d, 3H), 7.40 (d, 1H), 7.02 (d, 1H), 3.89 (s, 3H), 3.62 (m, 2H), 3.20 (m, 3H), 2.92 (s, 3H), 2.70 (s, 3H), 2.39 (s, 3H), 2.10 (m, 4H).

Example 2

N-[4-Methoxy-3-(4-piperidinyl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide

The product from description 4 (0.200g, 0.394 mmol) was suspended in a mixture of 10% sodium hydroxide solution (35 ml), THF (30 ml), and methanol (30 ml), and heated to reflux with stirring. After 24 h the reaction mixture was concentrated under reduced pressure and the aqueous residue was extracted with chloroform (2X). The combined organic layers were then dried (Na₂SO₄) and evaporated under reduced pressure to give a colourless oil, which was purified by silica-gel chromatography (200: 10: 1 CH₂Cl₂: MeOH: NH₃ as eluant) to give the **title compound** as a white solid (0.050g, 26%) m.pt. 183-184° C (from CHCl₃/60-80 Petrol)

¹H NMR (250 MHz, CDCl₃) δ (ppm): 7.98 (m, 5H), 7.62 (dd, 1H), 7.49 (d, 2H), 7.38 (m, 2H), 6.90 (d, 1H), 3.82 (s, 3H), 3.15 (m, 3H), 2.80 (m, 2H), 2.70 (s, 3H), 2.30 (s, 3H), 2.05 (s, 1H), 1.82 (m, 2H), 1.62 (m, 2H).

Example 3

N-[4-Methoxy-3-(1-methyl-1,2,3,6-tetrahydropyrid-4-yl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide

The product from description 6 (0.090g, 0.189 mmol) was dissolved in ethanol (6 ml) and was treated with methyl iodide (0.047 ml, 0.756 mmol) with stirring and was heated to reflux. After 4 h and 8 h, further amounts of methyl iodide were added (0.047 ml, 0.756 mmol) and (0.094 ml, 1.512 mmol) respectively. After 24 h, the reaction mixture was allowed to cool and was concentrated to approximately half volume. The resultant yellow precipitate was then filtered off, and washed with diethyl ether to give the crude quaternary salt. The crude quaternary salt was then dissolved in a mixture of water (2 ml) and ethanol (2 ml), cooled to 0° C, and then treated with sodium borohydride (0.008g, 0.200 mmol). After 0.25 and 0.5 h, further amounts of sodium borohydride (0.008g, 0.200 mmol) were added. The reaction mixture was treated with sodium hydrogen carbonate solution (10 ml), and water (10 ml). The resultant suspension was then extracted with chloroform (2 x 15 ml). The combined organic layers were then dried (Na₂SO₄) and evaporated under reduced pressure to give a colourless oil, which was purified by silica-gel chromatography (7.5% MeOH/CH₂Cl₂ as eluant) to give the title compound as a pale yellow oil (0.040g, 43%), which was converted to its oxalate salt.

m.pt. 192-194°C (oxalate salt)

¹H NMR (250 MHz, CDCl₃) (free base) δ (ppm): 7.95 (m, 4H), 7.85 (s, 1H), 7.63 (dd, 1H), 7.45 (d, 2H), 7.35 (m, 2H), 6.90 (d, 1H), 5.80 (s, 1H), 3.80 (s, 3H), 3.18 (m, 2H), 2.75-2.58 (m, 4H), 2.70 (s, 3H), 2.45 (s, 3H), 2.33 (s, 3H).

Example 4

N-[3-(8-Azabicyclo[3.2.1]octan-3-yl)-4-methoxyphenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide

The product from description 12 (0.194g, 0.319 mmol) was dissolved in dichloromethane (4 ml) and was treated with trifluoroacetic acid (2 ml) dropwise with stirring. After 20 h, the reaction mixture was evaporated under reduced pressure and the residue partitioned between sodium hydrogen carbonate solution and dichloromethane. The aqueous layer was extracted with dichloromethane (1X) and the combined organic layers were dried (Na₂SO₄) and evaporated under reduced pressure to give the title compound as a yellow oil (0.160g, 99%) which was subsequently converted to its oxalate salt.

35

m.pt. 230-232° C (oxalate salt)

¹H NMR (400 MHz, CD₃SOCD₃) (oxalate salt) δ (ppm): 10.20 (s, 1H), 8.08 (d, 2H), 7.98 (s, 1H), 7.91 (d, 1H), 7.82 (s, 1H), 7.65 (dd, 1H), 7.58 (d, 2H), 7.42 (d, 1H), 7.00 (d, 1H), 4.20 (br s, 2H), 4.04 (s, 2H), 3.80 (s, 3H), 3.35 (m, 1H), 2.70 (s, 3H), 2.42 (m, 2H), 2.35 (s, 3H), 1.95 (m, 4H), 1.85 (m, 2H).

5

Example 5

N-[4-Methoxy-3-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide

10 3-(5-Amino-2-methoxyphenyl)-8-methyl-8-azabicyclo[3.2.1]octane (D11, 0.232g, 0.943 mmol) was transformed to give the **title compound** (0.184g, 38%) as a white foam according to the method outlined in Example 1. The title compound was subsequently converted to its oxalate salt.

15 m.pt. 218-219° C (oxalate salt)

¹H NMR (400 MHz, CD₃SOCD₃) (oxalate salt) δ (ppm): 10.20 (s, 1H), 8.05 (d, 2H), 7.98 (s, 1H), 7.90 (m, 2H), 7.65 (dd, 1H), 7.55 (d, 2H), 7.41 (d, 1H), 7.00 (d, 1H), 4.45 (br s, 1H), 3.85 (s, 2H), 3.80 (s, 3H), 3.33 (m, 1H), 2.68 (s, 6H), 2.55 (m, 2H), 2.32 (s, 20 3H), 2.15 (m, 2H), 1.98 (m, 4H)

Example 6

[3,4-Dihydro-6-methoxy-7-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-2H-quinolin-1-yl]-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone

25

The product from description 14 (0.440g, 1.54 mmol) was transformed to give the **title compound** (0.710g, 82%) as a cream foam according to the methodology described in example 1 and was subsequently converted to its oxalate salt.

30 m.pt. 140-143° C (oxalate salt)

¹H NMR (400 MHz, CD₃SOCD₃ at 80°C) (oxalate salt) δ(ppm): 7.92 (s, 1H), 7.88 (dd, 1H), 7.48 (d, 2H), 7.37 (d, 2H), 7.32 (d, 1H), 6.88 (s, 1H), 6.84 (s, 1H), 3.80 (m, 5H), 3.66 (m, 2H), 3.25 (m, 1H), 2.85 (t, 2H), 2.67 (s, 3H), 2.58 (s, 3H), 2.40-2.25 (m, 2H), 35 2.32 (s, 3H), 2.10-1.98 (m, 4H), 1.60 (m, 2H), 1.48 (dd, 2H)

Example 7

[7-(8-Azabicyclo[3.2.1]octan-3-yl)-3,4-dihydro-6-methoxy-2H-quinolin-1-yl]-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone

5 The product from example 6 (0.350g, 0.623 mmol) was dissolved in dichloromethane (15 ml) and was treated with 1-chloroethyl chloroformate (0.086 ml, 0.795 mmol), followed by diisopropylethylamine (0.138 ml, 0.795 mmol) with stirring under argon. After 20 h, the reaction mixture was evaporated under reduced pressure and the resulting brown foam was dissolved in methanol (20 ml), and heated to reflux with stirring. After 1h, the reaction mixture was evaporated under reduced pressure and the brown oily residue was
10 purified by silica-gel chromatography (100:10:1 CH₂Cl₂: MeOH: NH₃ as eluant) to give the title compound as a pale yellow oil (0.201g, 59%), which was converted to its oxalate salt.

m.pt. 239-241° C (oxalate salt)

15 ¹H NMR (250 MHz, CDCl₃) (free base) δ(ppm): 7.98 (s, 1H), 7.92 (d, 1H), 7.42 (d, 2H), 7.25 (m, 4H), 6.61 (s, 1H), 3.92 (t, 2H), 3.79 (s, 3H), 3.58 (m, 2H), 3.20 (m, 1H), 2.83 (t, 2H), 2.68 (s, 3H), 2.32 (s, 3H), 2.10 (m, 6H), 1.80 (m, 2H), 1.42 (m, 2H), 0.95 (s, 1H).

20 **Example 8**

N-[3-(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide


8-Methyl-3-(3-aminophenyl)-8-azabicyclo[3.2.1]octane (D17, 0.104g, 0.481 mmol) was
25 transformed to give the title compound as a cream solid (0.130g, 55%) according to the method outlined in example 1, and was subsequently converted to its oxalate salt.

m.pt. 106-107°C (oxalate salt)

30 ¹H NMR (250 MHz, CDCl₃) (free base) δ (ppm): 8.00 (m, 5H), 7.72 (s, 1H), 7.47 (m, 3H), 7.35 (m, 2H), 7.13 (d, 1H), 3.48 (s, 2H), 3.15 (m, 1H), 2.70 (s, 3H), 2.60 (m, 2H), 2.38 (s, 3H), 2.33 (s, 3H), 2.05 (m, 2H), 1.88 (dd, 2H), 1.60 (d, 2H).

CLAIMS:

1. A compound of formula (I) or a salt thereof:



(I)

- 10 in which

R^1 is hydrogen, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, COC_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkoxy, acyl, nitro, trifluoromethyl, cyano, SR^9 , SOR^9 , SO_2R^9 , $SO_2NR^{10}R^{11}$, CO_2R^{10} , $NR^{10}SO_2R^{11}$, $CONR^{10}R^{11}$, $CO_2NR^{10}R^{11}$, $CONR^{10}(CH_2)_aCO_2R^{11}$, $(CH_2)_aNR^{10}R^{11}$,
 15 $(CH_2)_aCONR^{10}R^{11}$, $(CH_2)_aNR^{10}COR^{11}$, $(CH_2)_aCO_2C_{1-6}$ alkyl, $CO_2(CH_2)_aOR^{10}$, $CONHNR^{10}R^{11}$, $NR^{10}R^{11}$, $NR^{10}CO_2R^{11}$, $NR^{10}CO(CH_2)_aNR^{10}R^{11}$, $NR^{10}CONR^{10}R^{11}$, $CR^{10}=NOR^{11}$, $CNR^{10}=NOR^{11}$, where R^9 , R^{10} and R^{11} are independently hydrogen or C_{1-6} alkyl and a is 1 to 4 or R^1 is an optionally substituted 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen,

- 20 nitrogen or sulphur;

R^2 and R^3 are independently hydrogen, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, C_{1-6} alkyl OC_{1-6} alkyl, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO_2R^{10} , $CONR^{10}R^{11}$, $NR^{10}R^{11}$ where R^{10} and R^{11} are independently hydrogen or C_{1-6} alkyl;

- 25 R^4 is hydrogen or C_{1-6} alkyl and R^5 is hydrogen, halogen, hydroxy, C_{1-6} alkyl or C_{1-6} alkoxy or R^4 and R^5 together form a group -A- where A is $(CR^{12}R^{13})_q$ where q is 2, 3 or 4 and R^{12} and R^{13} are independently hydrogen or C_{1-6} alkyl or A is $(CR^{12}R^{13})_r-D$ where r is 0, 1, 2 or 3 and D is oxygen, sulphur or $CR^{12}=CR^{13}$;


R^6 is hydrogen, halogen, hydroxy, C_{1-6} alkyl or C_{1-6} alkoxy;

- 30 n is 1 or 2; and


R^7 is an optionally substituted 5 to 7-membered saturated or partially saturated heterocyclic ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen or sulphur or R^7 is an optionally substituted 6,6 or 6,5 bicyclic ring containing a nitrogen atom and optionally a further heteroatom selected from oxygen, nitrogen or sulphur.

- 35 2. A compound according to claim 1 in which R^1 is oxadiazolyl.

3. A compound according to claim 2 or 3 in which R^2 is C_{1-6} alkyl.
4. A compound according to any one of claims 1 to 3 in which R^3 is hydrogen.
5. A compound according to any one of claims 1 to 4 in which R^4 and R^5 are both hydrogen or R^4 with R^5 forms an ethyl or propyl group.
- 5 6. A compound according to any one of claims 1 to 5 in which R^6 is C_{1-6} alkoxy.
7. A compound according to any one of claims 1 to 6 in which R^7 is a piperidine, tetrahydropyridine, tropane or isoquinuclidine ring.
8. A compound according to claim 1 which is:
- 10 N-[4-Methoxy-3-(1-methyl-4-piperidinyl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
N-[4-Methoxy-3-(4-piperidinyl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
N-[4-Methoxy-3-(1-methyl-1,2,3,6-tetrahydropyrid-4-yl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
- 15 N-[3-(8-Azabicyclo[3.2.1]octan-3-yl)-4-methoxyphenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
N-[4-Methoxy-3-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
- 20 [3,4-Dihydro-6-methoxy-7-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-2H-quinolin-1-yl]-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone,
[7-(8-Azabicyclo[3.2.1]octan-3-yl)-3,4-dihydro-6-methoxy-2H-quinolin-1-yl]-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone,
N-[3-(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide,
- 25 or a pharmaceutically acceptable salt thereof.
9. A process for the preparation of a compound of formula (I) which comprises
 - (a) for compounds where R^4 is hydrogen or C_{1-6} alkyl and R^5 is hydrogen, halogen, hydroxy, C_{1-6} alkyl or C_{1-6} alkoxy, reaction of a compound of formula (II):



in which R^1 , R^2 and R^3 are as defined in formula (I) and L is a leaving group, with a compound of formula (III):




5

(III)

in which R^4 and R^5 are as defined above and R^6 , R^7 and n are as defined in formula (I);
or

- 10 (b) for compounds where R^4 together with R^5 forms a group A, reaction of a compound of formula (II) as defined above with a compound of formula (IV):



15

(IV)

in which A is as defined above and R^6 , R^7 and n are as defined in formula (I);
and optionally after (a) or (b) and in any order:

- converting a compound of formula (I) into another compound of formula (I)
 - forming a pharmaceutically acceptable salt.
- 20
10. A compound according to any one of claims 1 to 7 for use in therapy.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 96/01465

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D451/02 C07D271/06 A61K31/46 A61K31/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J.MED.CHEM., vol. 37, no. 15, 22 July 1994, WASHINGTON, pages 2253-2257, XP002008422 CLITHEROW, J.W. ET AL.: "Evolution of a Novel Series of [(N,N-Dimethylamino)propyl]- and Piperazinybenzanilides as the First Selective 5-HT1D Antagonists" * see page 2255, Table 2, compounds 9 - 11 * see the whole document	1-10
X	WO, A.94 15920 (GLAXO GROUP LTD ; CARTER MALCOLM (GB)) 21 July 1994 * overlap of main claims * see the whole document --- -/-	1-10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

16 July 1996

Date of mailing of the international search report

16.08.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Stellmach, J

INTERNATIONAL SEARCH REPORT

Int. onal Application No

PCT/EP 96/01465

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 533 268 (GLAXO GROUP LTD) 24 March 1993 cited in the application * overlap of main claims * see the whole document ---	1-10
X	EP,A,0 533 266 (GLAXO GROUP LTD) 24 March 1993 cited in the application * overlap of main claims * see the whole document ---	1-10
X	WO,A,95 04729 (SMITHKLINE BEECHAM PLC ;DUCKWORTH DAVID MALCOLM (GB); JENKINS SARA) 16 February 1995 * overlap of main claims * see the whole document ---	1-10
X	WO,A,95 06637 (SMITHKLINE BEECHAM PLC ;GASTER LARAMIE MARY (GB); DUCKWORTH DAVID) 9 March 1995 * overlap of main claims * see the whole document ---	1-10
X	WO,A,95 06644 (SMITHKLINE BEECHAM PLC ;DUCKWORTH DAVID MALCOLM (GB); GASTER LARAM) 9 March 1995 see the whole document ---	1-10
X	GB,A,2 276 162 (GLAXO GROUP LTD) 21 September 1994 see the whole document ---	1-10
Y	EP,A,0 533 267 (GLAXO GROUP LTD) 24 March 1993 cited in the application see the whole document ---	1-10
Y	GB,A,2 273 930 (GLAXO GROUP LTD) 6 July 1994 see the whole document ---	1-10
Y	WO,A,95 06044 (SMITHKLINE BEECHAM PLC ;DUCKWORTH DAVID MALCOLM (GB); GASTER LARAM) 2 March 1995 see the whole document ---	1-10
Y	GB,A,2 276 160 (GLAXO GROUP LTD) 21 September 1994 cited in the application see the whole document ---	1-10

	-/--	

INTERNATIONAL SEARCH REPORT

Int. onal Application No
PCT/EP 96/01465

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO,A,95 26328 (SMITHKLINE BEECHAM PLC ;GASTER LARAMIE MARY (GB); WYMAN PAUL ADRIA) 5 October 1995 see the whole document ---	1-10
P,X	WO,A,96 06079 (SMITHKLINE BEECHAM PLC ;GASTER LARAMIE MARY (GB)) 29 February 1996 see the whole document -----	1-10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 96/01465

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Formula I in claim 1 contains only a minor fixed part, which is not sufficiently limited by claims 2-7. Considering the large number of variables, the scope of said claims cannot be evaluated and an exhaustive search is not possible. Claims 1-7, 9-10 have been searched incompletely.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 96/01465

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9415920	21-07-94	AU-B- 5815594 CN-A- 1094037	15-08-94 26-10-94
EP-A-0533268	24-03-93	AP-A- 303 AU-B- 656021 AU-B- 2453092 CA-A- 2078505 HU-A- 65608 JP-A- 6116251 NZ-A- 244373 US-A- 5510350 US-A- 5340810 ZA-A- 9207108 CN-A- 1076195	28-01-94 19-01-95 25-03-93 19-03-93 28-07-94 26-04-94 28-03-95 23-04-96 23-08-94 08-09-93 15-09-93
EP-A-0533266	24-03-93	AU-B- 2452992 CA-A- 2078506 HU-A- 66319 JP-A- 6107649 US-A- 5356893 ZA-A- 9207107	25-03-93 19-03-93 28-11-94 19-04-94 18-10-94 08-09-93
WO-A-9504729	16-02-95	EP-A- 0712397	22-05-96
WO-A-9506637	09-03-95	EP-A- 0716650	19-06-96
WO-A-9506644	09-03-95	EP-A- 0716656	19-06-96
GB-A-2276162	21-09-94	NONE	
EP-A-0533267	24-03-93	AU-B- 2452892 AU-B- 2568792 CA-A- 2078507 CN-A- 1073430 CZ-A- 9400611 WO-A- 9306084 FI-A- 941261 JP-A- 6107637 NO-A- 940974 US-A- 5358948	25-03-93 27-04-93 19-03-93 23-06-93 16-11-94 01-04-93 17-03-94 19-04-94 17-03-94 25-10-94

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/01465

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0533267		ZA-A- 9207106	17-03-94
GB-A-2273930	06-07-94	NONE	
WO-A-9506044	02-03-95	EP-A- 0714389	05-06-96
GB-A-2276160	21-09-94	NONE	
WO-A-9526328	05-10-95	NONE	
WO-A-9606079	29-02-96	NONE	